文献速递糖尿病

非奈利酮与心力衰竭中新发糖尿病:FINEARTS-HF 试验的预设分析

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-01-13

FINEARTS-HF 预设分析纳入 3222 例基线无糖尿病的射血分数轻度降低或保留的心力衰竭患者,随机接受口服非奈利酮或安慰剂。中位随访 31.3 个月,非奈利酮组新发糖尿病风险较安慰剂组降低 24%(HR 0.76,95%CI 0.59-0.97,p=0.026)。

要点

  • 在无糖尿病的心力衰竭患者中,非奈利酮较安慰剂降低新发糖尿病风险。
  • 非奈利酮组新发糖尿病发生率 7.2%,安慰剂组 9.1%。
  • 竞争风险分析和敏感性分析结果与主要分析一致。

核心结论

  • 在无糖尿病的射血分数轻度降低或保留的心力衰竭患者中,口服非奈利酮较安慰剂降低新发糖尿病的风险,代表该治疗在这些个体中具有有意义的额外临床获益。

研究设计与样本

  • FINEARTS-HF 为随机、双盲、安慰剂对照试验,共 6001 例纽约心脏协会功能分级 II-IV 级、左心室射血分数 40% 或更高、有结构性心脏病证据且 N 末端 B 型利钠肽原升高的心力衰竭患者随机接受口服非奈利酮或安慰剂。
  • 本预设分析排除基线糖尿病(研究者报告的糖尿病史或基线 HbA1c ≥6.5%)患者,3222 例(53.7%)基线无糖尿病者构成研究人群。
  • 新发糖尿病定义为连续两次随访 HbA1c ≥6.5% 或新起始降糖治疗。
  • 主要分析采用全分析集(意向治疗),安全性分析集为至少接受一剂研究药物者(按实际治疗分析)。
  • 试验注册号 ClinicalTrials.gov NCT04435626,已停止招募新参与者。

主要发现

  • 中位随访 31.3 个月(IQR 21.5-36.3),非奈利酮组 115 例(7.2%)vs 安慰剂组 147 例(9.1%)发生新发糖尿病。
  • 非奈利酮组新发糖尿病发生率为 3.0 例/100 人年(95%CI 2.5-3.6)vs 安慰剂组 3.9 例/100 人年(95%CI 3.3-4.6)。
  • 与安慰剂相比,非奈利酮显著降低新发糖尿病风险 24%(HR 0.76,95%CI 0.59-0.97,p=0.026)。
  • Fine-Gray 竞争风险分析(考虑死亡竞争风险)结果相似(亚分布 HR 0.75,95%CI 0.59-0.96,p=0.024)。
  • 敏感性分析(扩展定义包括以糖尿病为适应证起始 SGLT2 抑制剂、仅限 HbA1c 测量、仅限新起始降糖药物)及排除基线使用降糖药物者(n=15)后结果相似;关键亚组间效应一致;7 例发生上述定义未捕获的新糖尿病不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA1c levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial. METHODS: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally. Randomisation was performed with concealed allocation. The primary outcome of the trial was the composite of cardiovascular death and total (first and recurrent) heart failure events (ie, heart failure hospitalisation or urgent heart failure visit). In the present analysis, participants with diabetes at baseline (investigator-reported history of diabetes or baseline HbA1c ≥6·5%) were excluded. New-onset diabetes was defined as a HbA1c measurement of 6·5% or higher on two consecutive follow-up visits or new initiation of glucose-lowering therapy. The full-analysis set comprised all participants randomly assigned to study treatment, analysed according to their treatment assignment irrespective of the treatment received (ie, intention to treat). The safety analysis set comprised participants randomly assigned to study treatment who took at least one dose of the investigational product, analysed according to the treatment actually received. This trial is registered with ClinicalTrials.gov, NCT04435626, and is closed to new participants. FINDINGS: Between Sept 14, 2020, and Jan 10, 2023, 6001 participants were recruited and randomly assigned to finerenone or placebo. 3222 (53·7%) participants did not have diabetes at baseline and comprised the study population. During a median duration of follow-up of 31·3 months (IQR 21·5-36·3), 115 (7·2%) participants in the finerenone group and 147 (9·1%) in the placebo group developed new-onset diabetes, corresponding to a rate of 3·0 events per 100 person-years (95% CI 2·5-3·6) in the finerenone group and 3·9 events per 100 person-years (3·3-4·6) in the placebo group. Compared with placebo, finerenone significantly reduced the hazard of new-onset diabetes by 24% (hazard ratio [HR] 0·76 [95% CI 0·59-0·97], p=0·026). Fine-Gray competing risk analysis, accounting for the competing risk of death, yielded a similar finding (subdistribution HR 0·75 [0·59-0·96], p=0·024). Results were similar in sensitivity analyses, in which the definition of new-onset diabetes was expanded to include initiation of SGLT2 inhibitor treatment with diabetes as indication, restricted to HbA1c measurements only, and restricted to new initiation of glucose-lowering drugs only (excluding SGLT2 inhibitor treatment). Findings were similar when participants treated with glucose-lowering drugs at baseline were excluded (n=15). The effect of finerenone, compared with placebo, on new-onset diabetes was consistent across key participant subgroups. Seven participants had an adverse event of new diabetes not captured by any of the definitions above. INTERPRETATION: In participants with heart failure with mildly reduced or preserved ejection fraction without diabetes, oral finerenone reduced the hazard of new-onset diabetes, representing a meaningful additional clinical benefit of this treatment in these individuals. FUNDING: Bayer.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Butt JH, Jhund PS, Henderson AD, et al. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025. PMID: 39818225. doi:10.1016/S2213-8587(24)00309-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。